logo 600X600.png
U.S. Neuropathic Pain Treatment Market to surpass US$ 2,994.0 Million by 2030, Says Coherent Market Insights (CMI)
March 06, 2023 09:20 ET | CMI
Burlingame, March 06, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights’ analysis, the U.S. neuropathic pain treatment market is estimated to be valued at US$ 2,064.9 Million in 2022...
logo long.jpg
Global Peripheral Neuropathy Treatment Market to Surpass US$ 2,425.9 Million by 2030, Says Coherent Market Insights (CMI)
June 21, 2022 08:40 ET | CMI
Seattle, June 21, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global peripheral neuropathy treatment market is estimated to be valued at US$ 1,795.10 million in 2022 and is...
Logo.png
Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles
January 14, 2021 18:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles  Diabetic...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at Upcoming Virtual Investor Conferences
June 16, 2020 08:37 ET | Aptinyx Inc.
EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
May 14, 2020 16:03 ET | Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
April 30, 2020 08:47 ET | Aptinyx Inc.
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 30, 2020 16:01 ET | Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
March 18, 2020 16:01 ET | Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at Upcoming Investor Conferences
November 14, 2019 07:57 ET | Aptinyx Inc.
EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
November 12, 2019 16:01 ET | Aptinyx Inc.
Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00...